The evidence for the use of long-term benzodiazepines in the setting of treatment-refractory anxiety disorders

American Psychiatric Association (APA) (1990) Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association (APA). APA. Available at: https:// books.google.com.au/books?id=FoTursyqFP8C (accessed 2021). Calcaterra NE and Barrow JC (2014) Classics in chemical neuroscience: Diazepam (valium). ACS Chemical Neuroscience 5(4): 253–260. Committee on the Review of Medicines (CRM) (1980) Systematic review of the benzodiazepines: Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines. British Medical Journal 280(6218): 910. Greenblatt D, Shader R, Divoll M, et al. (1981) Benzodiazepines: A summary of pharmacokinetic properties. British Journal of Clinical Pharmacology 11: 11S–16S. Hollister LE (1981) Benzodiazepines: An overview. British Journal of Clinical Pharmacology 11: 117S–119S. Laughren TP, Battey Y, Greenblatt DJ, et al. (1982) A controlled trial of diazepam withdrawal in chronically anxious outpatients. Acta Psychiatrica Scandinavica 65: 171–179. Maletzky BM and Klotter J (1976) Addiction to diazepam. International Journal of the Addictions 11: 95–115. Marks J (1983) The benzodiazepines: An international perspective. Journal of Psychoactive Drugs 15: 137–149. Rickels K (1983) Benzodiazepines in emotional disorders. Journal of Psychoactive Drugs 15: 49–54. Silberman E, Balon R, Starcevic V, et al. (2020) Benzodiazepines: It’s time to return to the evidence. The British Journal of Psychiatry 218: 125–127. Sullivan W (1963) WARNING IS ISSUED ON TRANQUILIZERS; Some of most popular drugs can be addictive, expert tells science meeting BUT VALUE IS STRESSED doctor at U.S. Center cites usefulness, but declares caution is necessary six are specified increases in doses WARNING IS ISSUED ON TRANQUILIZERS. New York Times, 30 December, p. 23. Tibrewal P, Haeusler C, Kanigere MK, et al. (2021a) Are the benefits of benzodiazepines for anxiety disorders underestimated and their risks overestimated? Australian and New Zealand Journal of Psychiatry 55: 1109–1110. Vorspan F, Barré T, Pariente A, et al. (2018) Faut-il limiter la durée des traitements par benzodiazépines ? La Presse Médicale 47(10): 892–898.